Karyopharm Therapeutics Inc. Stock
A very strong showing by Karyopharm Therapeutics Inc. today, with an increase of €0.044 (4.140%) compared to yesterday's price.
We see a rather positive sentiment for Karyopharm Therapeutics Inc. with 8 Buy predictions and 2 Sell predictions.
With a target price of 5 € there is potential for a 357.46% increase which would mean more than doubling the current price of 1.09 € for Karyopharm Therapeutics Inc..
Our community identified positive and negative aspects for Karyopharm Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Karyopharm Therapeutics Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Karyopharm Therapeutics Inc. | 4.140% | 1.844% | 1.303% | -52.230% | 25.960% | -86.180% | - |
Ardelyx Inc. | 1.540% | -5.213% | 13.498% | 74.307% | 23.945% | 27.929% | - |
Evolus Inc | -1.680% | -1.681% | 5.405% | 27.174% | 29.282% | 59.184% | - |
Salarius Pharmaceuticals Inc. | 0.530% | -7.729% | -10.748% | -66.491% | -31.171% | -98.449% | -99.993% |
Comments
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $4.00 to $3.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
News
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
Karyopharm Therapeutics (NASDAQ: KPTI)Q1 2024 Earnings CallMay 08, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com